Letrozole, Leuprorelin, and Palbociclib combination

The combination of letrozole, leuprorelin, and palbociclib is a multi-drug regimen used primarily for treating hormone receptor-positive (HR+), HER2-positive metastatic breast cancer. This combination therapy represents an important treatment option, particularly for patients who cannot tolerate first-line chemotherapy. ## Mechanism of Action This combination works through multiple complementary mechanisms: - **Letrozole** is an aromatase inhibitor that blocks estrogen production, reducing hormone stimulation of estrogen receptor-positive breast cancer cells[1][2]. - **Leuprorelin** (also known as leuprolide) is a luteinizing hormone-releasing hormone (LHRH) agonist that suppresses ovarian function in premenopausal women, effectively creating a postmenopausal hormonal state[1][2]. - **Palbociclib** is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that blocks cell cycle progression, preventing cancer cell division and growth[1][2][3]. ## Clinical Evidence The combination has shown promising results in clinical settings: - In a case report of a 50-year-old premenopausal woman with HER2-positive and HR-positive metastatic breast cancer who could not tolerate chemotherapy, this combination therapy led to symptom relief, normalized liver function, and partial tumor response[1][2]. - The patient's progression-free survival exceeded 14 months, with manageable side effects including Grade 3 neutropenia and Grade 2 thrombocytopenia[1]. - The MonarcHER phase II study demonstrated that CDK4/6 inhibitors combined with trastuzumab and endocrine therapy significantly increased overall response rate (33% vs 14%) and progression-free survival (8.3 months vs 5.7 months) compared to trastuzumab with chemotherapy in HER2-positive and HR-positive advanced breast cancer patients[2][4]. ## Administration The typical dosing regimen includes: - Palbociclib: 125 mg orally once daily on Days 1-21 of a 28-day cycle - Letrozole: 2.5 mg orally once daily throughout therapy - Leuprorelin: 3.75 mg subcutaneously every 4 weeks (or 3.6 mg every 28 days)[3] For premenopausal patients, the LHRH agonist (leuprorelin) typically starts 28 days prior to the aromatase inhibitor and continues throughout therapy[3]. ## Side Effects Common side effects include: - Neutropenia (most common, can be Grade 3-4) - Anemia - Thrombocytopenia - Fatigue - Diarrhea (manageable with medications like loperamide)[1][4] This combination therapy represents an important treatment option for HER2-positive and HR-positive metastatic breast cancer, particularly for premenopausal patients who cannot tolerate first-line chemotherapy.